Navigation Links
Erbitux Plus Chemo Improves Lung Cancer Outcomes
Date:5/31/2008

Survival extended 5 weeks; benefit seen in all subtypes of disease, researchers say

SATURDAY, May 31 (HealthDay News) -- The long-awaited results of a trial of the biologic drug Erbitux on patients with advanced non-small cell lung cancer show it prolonged survival by about five weeks when combined with chemotherapy.

Medical professionals have known the drug improved survival, but the question has been by how much.

"This will give us more options to treat patients with non-small cell lung cancer, for whom the prognosis is very poor. Five-year survival is less than 5 percent," said Dr. Shakun Malik, director of the lung cancer program at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C.

"We haven't had much happening in the treatment of lung cancer for a long time," she added. "We now have some tremendous progress being made, and most of this is from the addition of biological therapies."

"For lung cancer, a small step forward is a big step, but it's always a question - this is four or five weeks, what does that really mean?" said Dr. Karen Reckamp, an assistant professor of medicine at City of Hope Cancer Center in Duarte, Calif.

There have been other trials involving Erbitux with similar chemotherapy regimens which did not show any benefits. This is the second study that has shown an improvement, Reckamp said.

"We have other negative studies. How is this going to fit into our packet? It does show a survival benefit. The toxicities are probably relatively reasonable," Reckamp said. "I think it's a drug that, with some discussion and some careful understanding of how this trial is different, will be something we do utilize in the right patients."

Avastin (bevacizumab), which blocks blood supply to the tumor, is currently the only targeted therapy approved for this type of lung cancer. Erbitux would be the second such drug approved for this use. Erbitux is made by ImClone Systems Inc. and marketed by Merck in Europe. Merck funded the study.

Erbitux (cetuximab) affects the epidermal growth factor receptor, believed to play a role in this type of cancer. It is already approved for and used in patients with cancer of the colon and the head and neck.

The study involved 1,125 patients, almost all of whom had stage IV cancer. Participants were randomized to receive either platinum-based chemotherapy alone or chemotherapy plus Erbitux.

Those in the Erbitux group lived an average of 11.3 months vs. 10.1 months for those who received a placebo. The response rate was also better in those receiving Erbitux: 36.3 percent vs. 29.2 percent.

And unlike other targeted therapies, the benefit was seen in all subtypes of the disease, said the Austrian researchers, whose findings were released Saturday in Chicago at the annual meeting of the American Society of Clinical Oncology.

Lung cancer is the leading cause of cancer death in the United States, with roughly 30 percent of all cancer deaths linked to this type of malignancy, according to the Lung Cancer Alliance.

More information

Visit the National Cancer Institute for more on lung cancer.



SOURCES: Shakun Malik, M.D., director, lung cancer program, Lombardi Comprehensive Cancer Center, Washington, D.C.; Karen Reckamp, M.D., assistant professor, medicine, City of Hope Cancer Center, Duarte, Calif.; May 31, 2008, presentation, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
2. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
3. Avastin Added to Chemo Helps Women With Advanced Cancer
4. Chemo May Limit Fertility in Breast Cancer Survivors
5. OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer
6. Study suggests chemotherapy diminishes fertility in breast cancer patients
7. Antioxidant supplements may lessen benefit of radiation and chemotherapy
8. Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
9. Not All Colon Cancer Patients Need Chemotherapy: Study
10. Chemotherapy might help cancer vaccines work
11. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s ... dental services to 1,961 people during the April 22-23 event at the San Mateo ... Californians who experience barriers to care, CDA Cares educates the public and policymakers about ...
(Date:4/24/2017)... Illinois (PRWEB) , ... April 24, 2017 , ... Veteran ... What happened next changed her life forever. , In “Healing Tears,” James depicts every ... the advice of my attorney, I began journaling conversations and situations throughout my divorce,” ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP ... food supplements, announced its popular products are now available for purchase on StackedNutrition.com, ... prioritizes the use of premium natural ingredients in making all of its products. ...
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African ... now available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional ... popularized in ancient India and Siam. It spread across Asia and Africa quickly, and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, ... credentialing solutions, today announced that Kyle Allain has joined the company as Vice ... sales and operations, including provider, payor and managed care solutions. , A ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
Breaking Medicine Technology: